By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


OptiNose AS 

1020 Stony Hill Road
Third Floor, Suite 300
Yardley  Pennsylvania  19067  U.S.A.
Phone: 267-364-3500 Fax: 267-395-2119


Company News
OptiNose Announces FDA Approval Of XHANCE (Fluticasone Propionate) Nasal Spray For The Treatment Of Nasal Polyps 9/19/2017 8:33:04 AM
OptiNose Files for $100 Million IPO 9/19/2017 6:28:22 AM
OptiNose AS Rakes In $37 Million Series D 5/9/2017 7:35:53 AM
Michael F. Marino Joins OptiNose AS As Chief Legal Officer 2/9/2017 7:46:30 AM
OptiNose AS Announces FDA Acceptance For Filing Of The New Drug Application For OPN-375 1/31/2017 10:16:23 AM
OptiNose AS Appoints Keith Goldan As Chief Financial Officer 1/27/2017 8:19:53 AM
Tom Gibbs Joins OptiNose AS As Chief Commercial Officer 9/29/2016 12:45:51 PM
OptiNose AS Release: New Research Highlights The Burden Of Illness Suffered By Chronic Rhinosinusitis Patients 9/19/2016 11:14:27 AM
OptiNose AS Presents Data From Phase III Trials With Investigational Product Using Exhalation Delivery System Technology For Treatment In Patients With Chronic Rhinosinusitis (CRS) With And Without Nasal Polyps 9/16/2016 8:19:00 AM
OptiNose AS Announces Pipeline Project To Evaluate Nose-To-Brain Application Of Bi-Directional Breath Powered Technology Selected For Norwegian Government Funding 2/1/2016 10:13:59 AM